Are Your GLP-1 Patients Super Responders?
Reported by Medscape. Read the original →
The headline suggests a discussion or exploration of the concept of "super responders" among patients using GLP-1 therapies. It implies that there may be a subset of patients who experience significantly better outcomes from these treatments compared to others.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.